表紙
市場調查報告書

全球核醫學放射性同位元素(RI)市場:各種類、產品、應用領域、地區 - 成長,趨勢,預測(2018年∼2023年)

Nuclear Medicine Radioisotopes Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 661020
出版日期 內容資訊 英文 119 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球核醫學放射性同位元素(RI)市場:各種類、產品、應用領域、地區 - 成長,趨勢,預測(2018年∼2023年) Nuclear Medicine Radioisotopes Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年03月01日內容資訊: 英文 119 Pages
簡介

全球核醫學放射性同位元素(RI)市場,2017年價值139億美元,預計從2018年到2023年以12.3%的年複合成長率發展。2017年北美掌握整體約40%的佔有率成為最大市場,不過,預計在預測期間中亞太地區市場表示最大的成長率。

本報告提供全球核醫學放射性同位元素(RI)市場調查,各種類、應用領域、地區的市場規模的變化與預測,市場趨勢,成長要素、阻礙因素以及市場機會、課題分析,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 成長要素,阻礙因素,市場機會,課題

  • 市場成長要素
    • 癌症及心臟病的發病率上升
    • 核醫學的應用擴大
    • SPECT及PET的用途擴大
    • 針患者對健康的意識提升
  • 市場阻礙因素
    • 償付制度的複雜性
    • 法規上的課題
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 各類型
    • 鎝-99m(Tc-99m)
    • 鉈-201(Tl-201)
    • 碘(I-123)
    • 鎵-67(Ga-67)
    • 氟-18
    • 銣-82(Rb-82)
    • 其他
  • 各應用領域
    • 腫瘤
    • 心臟病
    • 淋巴瘤
    • 甲狀腺
    • 神經
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他地區

第8章 競爭情形

  • 合併及收購分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • Agfa-Gevaert Group
  • Braco
  • Cardiarc Ltd
  • Cardinal Health Inc.
  • CMR Naviscan (Gamma Medica Inc.)
  • Curium
  • Digirad Corporation
  • GE Healthcare
  • Nordion (Canada) Inc.
  • NTP Radioisotopes SOC Ltd
  • Positron Corp.
  • Segami Corporation
  • Siemens Healthcare

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 54625

Market Overview

Increasing cases of cancer and cardiac ailments are the major drivers for the nuclear medicines radioisotopes market. Nuclear medicine has a huge potential in treating cancer and cardiac diseases. Growth of medical imaging is an opportunity for the growth of the global nuclear medicine radioisotope market, as both markets are correlated. Radiopharmaceuticals are approved by the Food and Drug Administration (FDA) as either drugs or biologics. They meet the statutory definition of drugs under Section 1861(t) of the Social Security Act because they either are included in the various drug compendia or recognized by hospital medical staff as drugs. Historically, nuclear medicine has been well established as a therapeutic modality for thyroid cancer, Graves' disease, hyperthyroidism, and bone pain palliation, associated with skeletal metastasis. Hence, the broadening applications of radioisotopes are expected to propel market growth.

Scope of the Report

As per the scope of the report, medical radioisotopes are defined as safe radioactive substances that are primarily used in the diagnosis of medical conditions. These radioisotopes, used in a diagnosis, emit gamma rays of energy that are sufficient to escape from the body. The rays also have a short half-life, which is apt, since the rays can decay as soon as the imaging is completed.

Key Market Trends

Oncology Segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period

Radiotherapy can be used to treat various medical conditions, especially cancer, using radiation to weaken or destroy particular targeted cells. PET, which is a precise technique, uses isotopes produced in a cyclotron. It is highly used for a clinical role in oncology, with fluorine-18 as the tracer, and is proven to be the most accurate non-invasive method of detecting and evaluating most cancers. A new field for cancer treatment is targeted alpha therapy (TAT) or alpha radio-immunotherapy, especially for the control of dispersed cancers. Nuclear medicine is proven effective in oncology in several roles, spanning the course of the disease, including the characterization of a mass, staging, restaging, and monitoring of therapeutic response. Hence, owing to these associated factors, the oncology segment is expected to exhibit the fastest growth rate.

North America captured the Largest Market Share and is Expected to Retain its Dominance

North America captured the largest market share in the nuclear medicine radioisotopes market. The United States was the largest contributor to the revenue of North America, and is expected to retain its dominance owing to the higher procedural volume and increasing adoption of the nuclear medicine isotopes for various therapeutic applications. Bone scintigraphy is the next most common nuclear medicine procedure performed in the United States, but it represents only 17% of procedures. The volume of PET procedures in the United States is approximately 1.5 million per year. Oncology accounts for more than 90% of the PET and PET/CT procedures performed, whereas cardiology and neurology account for about 4% each. Canada is the largest producer of Technetium-99m. Due to the use of Tc-99m in radiopharmaceuticals, the market is expected to grow at a tremendous rate in Canada. 80% of the nuclear medicine market is driven by Tc-99m in various diagnostic procedures and treatments. Considering these factors associated with the United States and Canada, the North American market is expected to experience accelerated growth rates and market dominance.

Competitive Landscape

There is high competition among the players of the global nuclear medicine radioisotopes market. However, this competition is not by virtue of competitive pricing or product differentiation. Additionally, big players of the pharmaceutical and biotechnology industries are leveraging their huge capital reserves to venture into this market, which is further increasing the competition. GE Healthcare,NTP Radioisotopes SOC Ltd, Nordion (Canada) Inc., Siemens Healthcare, and Positron Corp. are some of the major players in the nuclear medicine radioisotopes market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidences of Cancer and Cardiac Disorders
    • 4.2.2 Widening Applications of Nuclear Medicine
    • 4.2.3 Increasing SPECT and PET Applications
    • 4.2.4 Increasing Patient Awareness for Healthcare
  • 4.3 Market Restraints
    • 4.3.1 Reimbursement Complications
    • 4.3.2 Regulatory Issues
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Type of Radioisotopes
    • 5.1.1 Technetium-99m (Tc-99m)
    • 5.1.2 Thallium-201 (Tl-201)
    • 5.1.3 Iodine (I-123)
    • 5.1.4 Fluorine-18
    • 5.1.5 Rubidium-82 (Rb-82)
    • 5.1.6 Iodine-131 (I-131)
    • 5.1.7 Lutetium-177 (Lu-177)
    • 5.1.8 Radium-223 (Ra-223) & Alpharadin
    • 5.1.9 Actinium-225 (Ac-225)
    • 5.1.10 Others
  • 5.2 Application
    • 5.2.1 Oncology
    • 5.2.2 Cardiology
    • 5.2.3 Lymphoma
    • 5.2.4 Thyroid
    • 5.2.5 Neurology
    • 5.2.6 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Agfa-Gevaert Group
    • 6.1.2 Cardiarc Ltd
    • 6.1.3 Digirad Corporation
    • 6.1.4 CMR Naviscan (Gamma Medica Inc.)
    • 6.1.5 GE Healthcare
    • 6.1.6 Positron Corp.
    • 6.1.7 Segami Corporation
    • 6.1.8 Siemens Healthcare GmBH
    • 6.1.9 Nordion (Canada) Inc.
    • 6.1.10 NTP Radioisotopes SOC Ltd
    • 6.1.11 Bracco S.p.A
    • 6.1.12 Cardinal Health Inc.
    • 6.1.13 Curium

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top